4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ergosterol peroxide from marine fungus Phoma sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As part of our ongoing search for novel therapeutic structures from microorganism, the chemical examination of marine fungus Phoma sp. resulted in the isolation of ergosterol, ergosterol peroxide (EP), and 9,11-dehydroergosterol peroxide (DEP). The bioassay results demonstrated that the three isolates reduced the viability of various cancer cells, with EP being highest in human lung cancer cell line A549 cells. EP induced caspase-dependent apoptosis through mitochondrial damage in A549 cells. Additionally, EP-induced ROS generation and apoptosis were attenuated by ROS-generating enzymes inhibitors and antioxidant N-acetylcysteine, indicated that ROS played an important role in EP-mediated apoptosis in A549 cells. Furthermore, it was observed that EP induced ROS-dependent autophagy, which attenuated apoptosis in A549 cells. On the other hand, EP reduced the LPS/ATP-induced proliferation and migration of A549 cells through attenuated NLRP3 inflammasome activity. Additionally, EP showed synergistic cytotoxic effect with antitumor drug Sorafenib in A549 cell viability inhibition. Furthermore, Micro-Western Array and Western blot analyses demonstrated that the protein levels of EGFR, HSP27, MEK5, AKT1, mTOR, Smad2, Smad3, TAB1, NF-κB, and HIF1-α decreased, while the levels of p-p38α, p-ERK1/2, p-JNK, fibronectin and p27 increased. Collectively, the results of this study demonstrated that EP might be useful to develop a therapeutic candidate for lung cancer complications.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

          Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, we describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in December 2005 - was completed in just 11 years, with approval being received approximately 5 years after the initiation of the first Phase I trial.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Apoptosis - the p53 network.

              Exposure to cellular stress can trigger the p53 tumor suppressor, a sequence-specific transcription factor, to induce cell growth arrest or apoptosis. The choice between these cellular responses is influenced by many factors, including the type of cell and stress, and the action of p53 co-activators. p53 stimulates a wide network of signals that act through two major apoptotic pathways. The extrinsic, death receptor pathway triggers the activation of a caspase cascade, and the intrinsic, mitochondrial pathway shifts the balance in the Bcl-2 family towards the pro-apoptotic members, promoting the formation of the apoptosome, and consequently caspase-mediated apoptosis. The impact of these two apoptotic pathways may be enhanced when they converge through Bid, which is a p53 target. The majority of these apoptotic effects are mediated through the induction of specific apoptotic target genes. However, p53 can also promote apoptosis by a transcription-independent mechanism under certain conditions. Thus, a multitude of mechanisms are employed by p53 to ensure efficient induction of apoptosis in a stage-, tissue- and stress-signal-specific manner. Manipulation of the apoptotic functions of p53 constitutes an attractive target for cancer therapy.
                Bookmark

                Author and article information

                Contributors
                kfhua@niu.edu.tw
                shwu@gate.sinica.edu.tw
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                18 December 2018
                18 December 2018
                2018
                : 8
                : 17956
                Affiliations
                [1 ]ISNI 0000 0001 2287 1366, GRID grid.28665.3f, Institute of Biological Chemistry, , Academia Sinica, ; Taipei, Taiwan
                [2 ]ISNI 0000 0001 2287 1366, GRID grid.28665.3f, Chemical Biology and Molecular Biophysics Program, , Taiwan International Graduate Program, Academia Sinica, ; Taipei, Taiwan
                [3 ]ISNI 0000 0004 0532 0580, GRID grid.38348.34, Department of Chemistry, , National Tsing Hua University, ; Hsinchu, Taiwan
                [4 ]Department of Laboratory Medicine, Linsen, Chinese Medicine and Kunming Branch, Taipei City Hospital, Taipei, Taiwan
                [5 ]ISNI 0000 0004 0639 3626, GRID grid.412063.2, Department of Biotechnology and Animal Science, , National Ilan University, ; Ilan, Taiwan
                [6 ]ISNI 0000 0004 0532 1428, GRID grid.265231.1, Department of Animal Science and Biotechnology, , Tunghai University, ; Taichung, Taiwan
                [7 ]ISNI 0000 0004 0634 0356, GRID grid.260565.2, Graduate Institute of Life Sciences, , National Defense Medical Center, ; Taipei, Taiwan
                [8 ]ISNI 0000 0001 1393 1398, GRID grid.417808.2, G.B. Elyakov Pacific Institute of Bioorganic Chemistry FEB RAS, ; Vladivostok, Russia
                [9 ]ISNI 0000 0004 0634 0356, GRID grid.260565.2, Department of Pathology, Tri-Service General Hospital, , National Defense Medical Center, ; Taipei, Taiwan
                [10 ]ISNI 0000 0004 0572 9415, GRID grid.411508.9, Department of Medical Research, , China Medical University Hospital, ; Taichung, Taiwan
                Author information
                http://orcid.org/0000-0001-9755-7961
                http://orcid.org/0000-0001-9770-6779
                http://orcid.org/0000-0001-8436-8299
                Article
                36411
                10.1038/s41598-018-36411-2
                6298985
                30560887
                c442ed01-e659-447d-bda2-20ea8a6bb9ca
                © The Author(s) 2018

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 November 2017
                : 21 November 2018
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100004663, Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan);
                Award ID: NSC-103-2923-M-001-006-MY3
                Award ID: NSC 103-2923-M-001-006-MY3
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2018

                Uncategorized
                Uncategorized

                Comments

                Comment on this article